Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,530.00    0.00 (0.00%)
Bid:
1,100.00
Ask:
2,200.00
Spread: 1,100.00 (100.00%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Director/PDMR Shareholding

26 Sep 2016 10:18

RNS Number : 8036K
Hikma Pharmaceuticals Plc
26 September 2016
 

Notification and public disclosure of transactions by persons discharging managerial responsibilities

The attached individual notification made under article 19.1 of the Market Abuse Regulation ("MAR") relates to the purchase by Darhold Limited of Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive, Vice Chairman and a Non-executive Director are directors of and shareholders in Darhold Limited. This announcement is made in accordance with article 19.3 of MAR.

Said Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Said Darwazah

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Chairman and Chief Executive is a director of and shareholder in Darhold Limited with an equity interest of 21.49%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 Mazen Darwazah

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mazen Darwazah

2

Reason for the notification

a)

Position/status

Executive Vice Chairman / PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Executive Vice Chairman is a director of and shareholder in Darhold Limited with an equity interest of 10.82%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

Mohammed 'Ali' Al-Husry

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Mohammed 'Ali' Al-Husry

2

Reason for the notification

a)

Position/status

Non-executive Director/ PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each

ID Code: GB00B0LCW083

b)

Nature of the transaction

 

Acquisition by Darhold Limited of 50,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC. The Non-Executive Director is a director of and shareholder in Darhold Limited with an equity interest of 7.95%.

c)

Price(s) and volume(s)

Price(s): £20.99

Volume(s): 50,000

d)

Aggregated information

Aggregated volume: 50,000

Price: £20.99

e)

Date of the transaction

23 September 2016

f)

Place of the transaction

London Stock Exchange (XLON)

 

Peter Speirs, Company Secretary, Responsible for releasing this announcement

26 September 2016

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGCGDCLBDBGLL
Date   Source Headline
22nd May 20207:00 amRNSHikma receives FDA approval for generic Vascepa®
20th May 20203:42 pmRNSDirector/PDMR Shareholding
13th May 20201:28 pmRNSDirector/PDMR Shareholding
1st May 202011:30 amRNSTotal Voting Rights
30th Apr 202012:00 pmRNSResult of AGM
30th Apr 20207:00 amRNSDirectorate Change
30th Apr 20207:00 amRNSTrading Statement
16th Apr 20203:07 pmRNSDirector/PDMR Shareholding
14th Apr 20202:30 pmRNSBlock listing Interim Review
2nd Apr 20207:00 amRNSAGM Update
31st Mar 20207:00 amRNSHikma's favourable ruling in generic Vascepa®
24th Mar 202010:52 amRNSDirector/PDMR Shareholding
19th Mar 202012:00 pmRNSAnnual Financial Report
28th Feb 202012:27 pmRNSDirector/PDMR Shareholding
28th Feb 202012:26 pmRNSDirector/PDMR Shareholding
28th Feb 202012:23 pmRNSDirector/PDMR Shareholding
27th Feb 20204:40 pmRNSDirector/PDMR Shareholding
27th Feb 20204:35 pmRNSBoard Committee Changes
27th Feb 20207:05 amRNSHikma enters agreement to commercialise Ryaltris™
27th Feb 20207:00 amRNSFinal Results
4th Feb 20202:06 pmRNSTotal Voting Rights
4th Feb 20209:07 amRNSNotice of Results
15th Jan 20209:46 amRNSDirector/PDMR Shareholding
15th Jan 20209:44 amRNSDirector/PDMR Shareholding
9th Jan 20208:00 amRNSHikma announces agreement with Arecor
2nd Jan 202010:56 amRNSTotal Voting Rights
10th Dec 201912:06 pmRNSCivica Rx and Hikma announce shipment of medicines
2nd Dec 20195:12 pmRNSTotal Voting Rights
27th Nov 20197:00 amRNSHikma completes FDA response for generic Advair®
21st Nov 20192:47 pmRNSDirector/PDMR Shareholding
8th Nov 201911:17 amRNSBlock Listing Application
7th Nov 20197:00 amRNSTrading Statement
5th Nov 20199:34 amRNSTotal Voting Rights
4th Oct 20191:36 pmRNSHolding(s) in Company
1st Oct 20193:15 pmRNSBlock listing Interim Review
1st Oct 20193:02 pmRNSTotal Voting Rights
17th Sep 20199:00 amRNSHikma launches prefilled syringes in the US
10th Sep 201910:05 amRNSNotice of Accession of Guarantor
6th Sep 20193:25 pmRNSDirector/PDMR Shareholding
2nd Sep 20195:13 pmRNSTotal Voting Rights
13th Aug 201910:20 amRNSDirector/PDMR Shareholding
9th Aug 20199:00 amRNSHikma expands nasal spray capabilities
9th Aug 20197:00 amRNSHalf-year Report
1st Aug 20193:04 pmRNSTotal Voting Rights
25th Jul 20197:00 amRNSHikma and Richter sign agreement for cariprazine
23rd Jul 20199:00 amRNSHikma and Civica Rx sign long-term agreement
8th Jul 20199:00 amRNSNotice of Results
2nd Jul 20195:54 pmRNSTotal Voting Rights
3rd Jun 20194:29 pmRNSTotal Voting Rights
17th May 20194:09 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.